Luye Pharma boosts convertible to $300m

Hong Kong-listed Luye Pharma Group sealed a convertible bond on Monday night, raising $300m from the increased deal.

  • By Jonathan Breen
  • 25 Jun 2019

Unrated Luye was looking to raise $250m from a five year non-call three convertible bond. The deal, while not jumbo for the asset class, was relatively large for Luye, representing 9% of its share capital pre-deal and around 20 days trading volume in the company’s stock.

Given the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Panda Bonds Top Arrangers

Rank Arranger Share % by Volume
1 Bank of China (BOC) 21.85
2 China Merchants Securities Co 14.67
3 Industrial and Commercial Bank of China (ICBC) 14.44
4 Agricultural Bank of China (ABC) 8.89
5 China Securities 7.41

Bookrunners of Asia-Pac (ex-Japan) ECM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 CITIC Securities 9,346.38 46 7.81%
2 Goldman Sachs 8,791.68 35 7.35%
3 Morgan Stanley 7,131.69 47 5.96%
4 China International Capital Corp Ltd 6,923.83 42 5.79%
5 UBS 6,281.96 46 5.25%

Bookrunners of Asia Pacific (ex-Japan) G3 DCM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 HSBC 21,140.46 182 8.46%
2 Citi 15,676.35 116 6.28%
3 JPMorgan 13,488.58 90 5.40%
4 Standard Chartered Bank 10,193.35 102 4.08%
5 Bank of America Merrill Lynch 9,668.56 74 3.87%

Asian polls & awards